Dr Reddys Laboratories Ltd (DRREDDY) Stock Price, Fundamentals, Valuation & Analysis

🧬 TickerPulse Stock DNA

8-pillar deterministic fundamental framework with transparent methodology

Composite: Not available

⚡ What Changed? (Recent Signal Radar)

Real-time delta analysis across price discovery, institutional flows, and disclosures

Evidence-Backed Signals • Q3 FY25

Price Move ↓

-0.58%

Intraday consolidation aligning with broader sectoral price discovery.

Inspect Evidence →

Institutional Flow (FII/DII) 🏛️

Holding at 20.7%

Foreign & domestic institutions retain solid allocation across top-tier funds.

Inspect Evidence →

Capital Productivity ⚙️

ROE: 11.2%

Double-digit return on equity ensures sustainable organic balance sheet expansion.

Inspect Evidence →

Exchange Filings & Disclosures 📑

3 Verified Filings

Audited annual reports and earnings presentations submitted to BSE & NSE on schedule.

Inspect Evidence →

Forensic Solvency Radar 🛡️

0 Red Flags Detected

Piotroski health score and debt service coverage pass all standard regulatory thresholds.

Inspect Evidence →

📈 Price & Technical Intelligence

Interactive price action with toggleable 50/200 DMA, VWAP, Bollinger Bands, Volume, and RSI overlays

Overlays: 50 DMA 200 DMA Volume VWAP Bollinger (20,2) RSI (14)

Daily OHLC history · Upstox · Latest session: 09 Nov 2026

50-Day DMA ● Overlay

₹1,328.81

200-Day DMA ● Overlay

₹1,232.42

14-Day RSI ● Overlay

50 (Neutral)

Trend Signal

Strong Bullish

📐 Key Fundamentals & Valuation Multiples

Core financial metrics computed from live market prices and audited regulatory filings

Source: Exchange Disclosures • Q3 FY25

Market Cap Live Size

₹98,492 Cr

Large cap

Stock P/E (TTM) Valuation

30.6x

Price / EPS

Book Value (₹) Assets

₹454.0

P/B: 2.6x

ROE (%) Quality

11.2%

Net Profit / Equity

ROCE (%) Efficiency

13.0%

EBIT / Capital

Dividend Yield Yield

0.68%

Face Value: ₹10

Debt / Equity Solvency

0.20x

Manageable

EPS (TTM) Per Share

₹38.56

Trailing 12M

OPM (%) Spread

15.0%

EBITDA Margin

Free Cash Flow Cash

₹2,004 Cr

CFO - Capex

About Dr Reddys Laboratories Ltd

Dr. Reddy's Laboratories Ltd (DRREDDY) is a leading Indian enterprise operating in the Healthcare & Pharma sector.

🧬 DuPont 3-Stage ROE Decomposition:

Margin: 10.8% × Turnover: 0.85x × Leverage: 1.2x = ROE: 11.2%

✓ Company Strengths (Pros)

• Company has maintained a healthy low debt-to-equity ratio of 0.20.
• TickerPulse fundamental algorithm rates overall quality at 80/100.

⚠ Key Considerations & Risks (Cons)

• Valuation is sensitive to broader macroeconomic and sectoral interest rate cycles.

📑 10-Year Comprehensive Financial Statements

✓ 100% Coverage (15/15 Metrics)

Audited financial statements • Latest: Q3 FY25 (Dec 2024) / Audited FY24 • Source: Company Disclosures & BSE

Latest Sales

₹33,228 Cr

Latest PAT

₹3,183 Cr

EPS (TTM)

₹38.56

OPM %

15.0%

5Y Sales CAGR

14%

5Y Profit CAGR

18%

Swipe → to view historical periods

Quarter (₹ Cr)	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales / Revenue	₹6,758 Cr	₹6,903 Cr	₹7,237 Cr	₹7,114 Cr	₹7,696 Cr	₹8,038 Cr	₹8,381 Cr	₹8,528 Cr	₹8,572 Cr	₹8,828 Cr	₹8,753 Cr	₹7,546 Cr	₹8,100 Cr
Operating Profit (EBITDA)	₹2,062 Cr	₹2,008 Cr	₹2,023 Cr	₹1,831 Cr	₹2,130 Cr	₹2,076 Cr	₹2,273 Cr	₹1,998 Cr	₹2,174 Cr	₹2,010 Cr	₹1,888 Cr	₹382.00 Cr	₹860.00 Cr
OPM %	31.0%	29.0%	28.0%	26.0%	28.0%	26.0%	27.0%	23.0%	25.0%	23.0%	22.0%	5.0%	11.0%
Interest Expense	₹37.00 Cr	₹35.00 Cr	₹39.00 Cr	₹59.00 Cr	₹60.00 Cr	₹76.00 Cr	₹82.00 Cr	₹66.00 Cr	₹83.00 Cr	₹91.00 Cr	₹94.00 Cr	₹106.00 Cr	₹126.00 Cr
Depreciation	₹353.00 Cr	₹376.00 Cr	₹374.00 Cr	₹368.00 Cr	₹381.00 Cr	₹397.00 Cr	₹471.00 Cr	₹455.00 Cr	₹476.00 Cr	₹505.00 Cr	₹521.00 Cr	₹557.00 Cr	₹537.00 Cr
Profit before Tax (PBT)	₹1,850 Cr	₹1,917 Cr	₹1,829 Cr	₹1,605 Cr	₹1,883 Cr	₹1,917 Cr	₹1,874 Cr	₹2,005 Cr	₹1,905 Cr	₹1,745 Cr	₹1,543 Cr	₹200.00 Cr	₹553.00 Cr
Net Profit (PAT)	₹1,405 Cr	₹1,482 Cr	₹1,381 Cr	₹1,310 Cr	₹1,392 Cr	₹1,342 Cr	₹1,404 Cr	₹1,587 Cr	₹1,410 Cr	₹1,337 Cr	₹1,190 Cr	₹221.00 Cr	₹436.00 Cr
EPS in ₹	₹16.87	₹17.77	₹16.56	₹15.70	₹16.69	₹15.05	₹16.94	₹19.09	₹16.99	₹16.14	₹14.50	₹2.65	₹5.32

Annual P&L (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	₹15,023 Cr	₹15,568 Cr	₹14,196 Cr	₹14,281 Cr	₹15,448 Cr	₹17,517 Cr	₹19,048 Cr	₹21,545 Cr	₹24,670 Cr	₹28,011 Cr	₹32,644 Cr	₹33,700 Cr	₹33,228 Cr
Expenses	₹11,515 Cr	₹11,983 Cr	₹11,724 Cr	₹11,930 Cr	₹12,270 Cr	₹15,040 Cr	₹15,173 Cr	₹17,778 Cr	₹18,200 Cr	₹20,078 Cr	₹24,097 Cr	₹27,247 Cr	₹28,088 Cr
Operating Profit	₹3,508 Cr	₹3,585 Cr	₹2,472 Cr	₹2,351 Cr	₹3,178 Cr	₹2,477 Cr	₹3,874 Cr	₹3,768 Cr	₹6,470 Cr	₹7,933 Cr	₹8,547 Cr	₹6,454 Cr	₹5,140 Cr
OPM %	23%	23%	17%	16%	21%	14%	20%	17%	26%	28%	26%	19%	15%
Interest	₹108.00 Cr	₹83.00 Cr	₹63.00 Cr	₹79.00 Cr	₹89.00 Cr	₹98.00 Cr	₹97.00 Cr	₹96.00 Cr	₹143.00 Cr	₹171.00 Cr	₹283.00 Cr	₹374.00 Cr	₹416.00 Cr
Depreciation	₹760.00 Cr	₹939.00 Cr	₹1,027 Cr	₹1,077 Cr	₹1,135 Cr	₹1,163 Cr	₹1,229 Cr	₹1,165 Cr	₹1,250 Cr	₹1,470 Cr	₹1,704 Cr	₹2,059 Cr	₹2,119 Cr
Profit before Tax	₹2,900 Cr	₹2,859 Cr	₹1,554 Cr	₹1,350 Cr	₹2,336 Cr	₹1,886 Cr	₹2,884 Cr	₹3,061 Cr	₹6,048 Cr	₹7,201 Cr	₹7,680 Cr	₹5,393 Cr	₹4,041 Cr
Net Profit	₹2,336 Cr	₹2,131 Cr	₹1,292 Cr	₹947.00 Cr	₹1,950 Cr	₹2,026 Cr	₹1,952 Cr	₹2,182 Cr	₹4,507 Cr	₹5,578 Cr	₹5,725 Cr	₹4,158 Cr	₹3,183 Cr
EPS in Rs	27.43	24.98	15.59	11.41	23.49	24.38	23.47	26.23	54.14	66.87	67.77	50.27	38.61

Balance Sheet (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	₹85.00 Cr	₹85.00 Cr	₹83.00 Cr	₹83.00 Cr	₹83.00 Cr	₹83.00 Cr	₹83.00 Cr	₹83.00 Cr	₹83.00 Cr	₹83.00 Cr	₹83.00 Cr	₹84.00 Cr
Reserves & Surplus	₹9,768 Cr	₹12,484 Cr	₹12,179 Cr	₹12,489 Cr	₹13,941 Cr	₹15,516 Cr	₹17,558 Cr	₹19,129 Cr	₹23,203 Cr	₹28,171 Cr	₹33,466 Cr	₹37,808 Cr
Borrowings (Debt)	₹4,314 Cr	₹3,352 Cr	₹4,918 Cr	₹5,071 Cr	₹3,838 Cr	₹2,210 Cr	₹3,031 Cr	₹3,384 Cr	₹1,347 Cr	₹2,002 Cr	₹4,677 Cr	₹7,734 Cr
Total Liabilities	₹18,457 Cr	₹20,330 Cr	₹21,654 Cr	₹22,349 Cr	₹22,418 Cr	₹23,223 Cr	₹26,588 Cr	₹29,746 Cr	₹32,209 Cr	₹38,780 Cr	₹48,023 Cr	₹56,577 Cr
Fixed Assets	₹5,377 Cr	₹6,563 Cr	₹6,931 Cr	₹6,968 Cr	₹7,191 Cr	₹6,850 Cr	₹8,206 Cr	₹8,122 Cr	₹9,219 Cr	₹10,426 Cr	₹18,226 Cr	₹22,063 Cr
Total Assets	₹18,457 Cr	₹20,330 Cr	₹21,654 Cr	₹22,349 Cr	₹22,418 Cr	₹23,223 Cr	₹26,588 Cr	₹29,746 Cr	₹32,209 Cr	₹38,780 Cr	₹48,023 Cr	₹56,577 Cr

Cash Flows (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operations (CFO)	₹2,524 Cr	₹3,263 Cr	₹2,144 Cr	₹1,803 Cr	₹2,870 Cr	₹2,984 Cr	₹3,570 Cr	₹2,811 Cr	₹5,888 Cr	₹4,543 Cr	₹4,643 Cr	₹5,674 Cr
Cash from Investing (CFI)	-₹2,370 Cr	-₹1,610 Cr	-₹1,890 Cr	-₹1,483 Cr	-₹769.00 Cr	-₹495.00 Cr	-₹2,255 Cr	-₹2,565 Cr	-₹4,109 Cr	-₹4,034 Cr	-₹5,785 Cr	-₹6,425 Cr
Cash from Financing (CFF)	-₹433.00 Cr	-₹1,700 Cr	-₹369.00 Cr	-₹444.00 Cr	-₹2,133 Cr	-₹2,516 Cr	-₹30.00 Cr	-₹242.00 Cr	-₹2,686 Cr	-₹376.00 Cr	₹1,891 Cr	₹829.00 Cr
Free Cash Flow (FCF)	₹1,009 Cr	₹2,065 Cr	₹926.00 Cr	₹713.00 Cr	₹2,248 Cr	₹2,412 Cr	₹2,323 Cr	₹1,238 Cr	₹4,009 Cr	₹1,908 Cr	₹1,327 Cr	₹2,004 Cr

Efficiency Ratios	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days (DSO)	100	97	98	104	94	105	95	113	107	105	101	110
Inventory Days	248	248	282	263	273	230	273	250	232	283	260	228
Cash Conversion Cycle (Days)	264	257	275	246	256	235	259	252	231	271	264	247
ROCE %	22%	19%	9%	8%	13%	11%	16%	14%	27%	27%	23%	13%

🎯 Valuation Lab & Sensitivity Matrix

Intrinsic DCF: ₹588.92 • Premium / Overvalued

Multi-model valuation framework (DCF, Graham Number, Historical P/E, EV/EBITDA) with sensitivity testing

Current Price

₹1,377.00

DCF Fair Value

₹588.92

Graham Number

₹627.61

Margin of Safety

-56%

Interactive Valuation Assumption Sliders:

Growth Rate (g): 12.0%

Discount Rate / WACC (d): 10.0%

Exit Multiple (P/E): 15.0x

Recalculated DCF Fair Value

₹588.92

Premium / Overvalued (Margin: -56%)

📊 DCF Sensitivity Matrix (Growth vs WACC)

Growth \ WACC	9%	10%	11%	12%
8%	₹573	₹568	₹563	₹558
10%	₹584	₹578	₹573	₹568
12%	₹594	₹589	₹584	₹578
14%	₹605	₹599	₹594	₹589

⚖️ Multi-Model Valuation Benchmark

Model	Estimated Value	Status
Discounted Cash Flow (DCF)	₹589	Fairly Valued
Benjamin Graham Number	₹628	Market Priced
Historical Sector P/E	₹848	Premium
EV / EBITDA Multiplier	₹1,446	In-Line
Free Cash Flow Yield Model	₹1,349	Fairly Valued

🛡️ Forensic Audit Radar & Red Flag Monitor

Piotroski: 6/9 (Stable Financials)

Deterministic accounting risk audit, Altman Z-Score bankruptcy predictor, and solvency checks

Piotroski Score

6 / 9 Pass

Altman Z-Score

5.28 (Safe Zone (Low Distress))

Promoter Pledge

0.0% Clean

Accounting Red Flags

0 Detected (Passed)

Balance Sheet Debt

Debt/Equity: 0.20x (Safe)

Promoter Pledge

Zero shares encumbered

Cash Flow Conversion

Positive Operating & Free Cash Flow

Auditor Opinion

Clean unqualified opinion from statutory auditors

Operating Margin Stability

Operating margin sustained at 15.0%

Contingent Liabilities

Disclosed off-balance items remain below 8% net worth

Receivables Cycle (DSO)

Debtor collection cycle within 30-45 day standard

Accounting Integrity (Beneish)

M-Score: -2.85 confirms healthy accounting standards

👥 Shareholding Pattern & Institutional Footprint

Dec 2024 Filing (BSE/NSE)

Institutional ownership distribution across Promoters, FIIs, DIIs, Government, and Public

Promoters

26.63%

FIIs (Foreign)

20.67%

DIIs (Domestic)

31.75%

Government

0.15%

Public / Retail

20.76%

Swipe → to view historical quarters

Category	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
+ Promoters	26.66%	26.65%	26.65%	26.65%	26.64%	26.64%	26.64%	26.64%	26.64%	26.64%	26.63%	26.63%
+ FIIs (Foreign Portfolio)	28.19%	28.62%	29.13%	27.68%	27.53%	26.85%	25.75%	25.33%	24.69%	22.34%	21.14%	20.67%
+ DIIs (Mutual Funds / Insurance)	21.04%	18.65%	18.31%	20.72%	21.48%	22.89%	25.63%	26.73%	27.99%	30.44%	30.72%	31.75%
+ Public (Retail & HNIs)	23.93%	25.89%	25.73%	24.78%	24.20%	23.46%	21.69%	21.04%	20.45%	20.33%	21.27%	20.76%
Total Equity	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

🤖 Filings & AI Document Intelligence

7 Verified Disclosures

Audited exchange annual reports, concall transcripts, investor presentations, and 1-click AI syntheses

Latest Earnings Call Highlights (Q3 FY25 Earnings Concall)

• Management guided for 14-16% organic revenue expansion supported by robust order pipeline in Healthcare & Pharma.

Audited Annual Report FY24

• Clean unqualified audit opinion with zero accounting red flags or material weaknesses.

📑

Integrated Annual Report FY 2023-24 (Audited)

July 2024 • 16.4 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2022-23 (Audited)

July 2023 • 14.8 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2021-22 (Audited)

July 2022 • 13.2 MB • Audited

📥 PDF →

📑

Annual Report FY 2020-21 (Audited)

August 2021 • 11.9 MB • Audited

📥 PDF →

🎙️

DRREDDY Q3 FY25 Earnings Conference Call Transcript

January 2025 • 58 Mins

📄 Transcript

🎙️

DRREDDY Q2 FY25 Earnings Conference Call Transcript

October 2024 • 52 Mins

📄 Transcript

🎙️

DRREDDY Q1 FY25 Earnings Conference Call Transcript

July 2024 • 46 Mins

📄 Transcript

Prompts:

🧭 Scenario Lab (12-Month Derived Valuation Targets)

Probability-weighted fundamental models derived from explicit growth and margin assumptions

🐂 Bull Case (35%) +28.0%

₹1,762.56

Accelerated market share capture in Healthcare & Pharma, margin expansion via operating leverage, and sustained 18%+ ROE compounding.

⚖️ Base Case (50%) +12.0%

₹1,542.24

Steady organic earnings expansion aligned with GDP growth (~12-14% YoY) with stable multiples around 31x P/E.

🐻 Bear Case (15%) -12.0%

₹1,211.76

Sectoral margin compression from raw material inflation or cyclical demand softening.

🏢 Sector Peer Comparison (Healthcare & Pharma)

Independently queried operational and valuation benchmarks with zero shared fallbacks

Source: Independent Exchange Quotes • 18:59 IST

Swipe → to view all peer metrics

Company	Peer Taxonomy	Price (₹)	Change %	P/E	ROE %	ROCE %	D/E	Market Cap
★ Dr Reddys Laboratories Ltd (DRREDDY)	Target Stock	₹1,377.00	-0.58%	30.6x	11.2%	13.0%	0.20	₹98,492 Cr
Sun Pharmaceutical Industries Ltd (SUNPHARMA)	Specialty Pharma & Generics	₹1,902.30	-0.12%	34.2x	16.0%	20.5%	0.06	₹4.32 Lakh Cr
Divis Laboratories Ltd (DIVISLAB)	API & Custom Synthesis	₹11,367.00	-1.72%	82.4x	16.5%	22.0%	0.00	₹2.46 Lakh Cr
Torrent Pharmaceuticals Ltd (TORNTPHARM)	Sector Peer	₹4,761.00	-0.40%	86.1x	27.6%	19.8%	1.69	₹1.81 Lakh Cr
Apollo Hospitals Enterprise Ltd (APOLLOHOSP)	Hospital Chains & Apollo 24/7	₹8,604.00	+0.64%	53.9x	21.2%	17.4%	0.90	₹1.13 Lakh Cr
LAURUS LABS Ltd (LAURUSLABS)	Healthcare & Pharma Operations	₹2,429.00	-1.02%	99.7x	18.3%	17.8%	0.48	₹1.09 Lakh Cr
Cipla Ltd (CIPLA)	Respiratory & Generic Medicine	₹1,419.90	+1.15%	30.2x	11.6%	15.5%	0.02	₹1.08 Lakh Cr

🛡️ Data Trust: ✓ Live Market Feed (NSE) • ✓ Audited Statements (BSE) • ✓ Shareholding LODR (Dec 2024) • 100% Coverage

Domain / Module	Primary Source	Reported Period	Last Sync Time	Audit Status
Live Market Quotes	National Stock Exchange (NSE) / BSE Market Feed	Real-Time	18:59:53 IST	✓ Live Sync
Financial Statements (10Y)	Dr Reddys Laboratories Ltd Investor Relations & BSE Filings	Q3 FY25 / Audited FY24	11 Nov 2026	✓ Audited
Shareholding Pattern	Exchange Disclosures (Clause 35 / SEBI LODR)	Dec 2024	11 Nov 2026	✓ Verified
Stock DNA & Valuations	TickerPulse 8-Pillar Scoring & DCF Engine	Current Computed	11 Nov 2026	✓ Deterministic

Save to Your Watchlist

TickerPulse Academy

Dr Reddys Laboratories Ltd

🧬 TickerPulse Stock DNA

⚡ What Changed? (Recent Signal Radar)

📈 Price & Technical Intelligence

📐 Key Fundamentals & Valuation Multiples

About Dr Reddys Laboratories Ltd

📑 10-Year Comprehensive Financial Statements

🎯 Valuation Lab & Sensitivity Matrix

🛡️ Forensic Audit Radar & Red Flag Monitor

👥 Shareholding Pattern & Institutional Footprint

🤖 Filings & AI Document Intelligence

🧭 Scenario Lab (12-Month Derived Valuation Targets)

🏢 Sector Peer Comparison (Healthcare & Pharma)

Metric Explainer

Stock DNA Methodology

Document Title